Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Monday, November 4th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.39 per share for the quarter. Supernus Pharmaceuticals has set its FY 2024 guidance at EPS.Investors interested in listening to the company's earnings conference call can do so using this link.
Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company had revenue of $168.30 million during the quarter, compared to analysts' expectations of $148.83 million. During the same quarter in the previous year, the company earned ($0.02) EPS. The firm's quarterly revenue was up 24.1% compared to the same quarter last year. On average, analysts expect Supernus Pharmaceuticals to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Supernus Pharmaceuticals Stock Up 0.4 %
Supernus Pharmaceuticals stock opened at $33.93 on Monday. Supernus Pharmaceuticals has a 12 month low of $21.99 and a 12 month high of $35.44. The company's fifty day simple moving average is $33.05 and its 200-day simple moving average is $30.31. The stock has a market cap of $1.87 billion, a P/E ratio of -117.00 and a beta of 0.88.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on SUPN. Piper Sandler reaffirmed a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen restated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th.
Check Out Our Latest Stock Report on Supernus Pharmaceuticals
Supernus Pharmaceuticals Company Profile
(
Get Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
